{"id":"NCT01430754","sponsor":"Vanda Pharmaceuticals","briefTitle":"Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder","officialTitle":"A Randomized Withdrawal Study to Demonstrate the Maintenance of Effect of 20 mg Tasimelteon in the Treatment of N24HSWD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2011-09-08","resultsPosted":"2014-10-10","lastUpdate":"2014-10-10"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-24-Hour Sleep-Wake Disorder"],"interventions":[{"type":"DRUG","name":"tasimelteon","otherNames":["VEC-162"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"tasimelteon","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.","primaryOutcome":{"measure":"Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.","timeFrame":"Approximately 12 weeks","effectByArm":[{"arm":"Tasimelteon","deltaMin":9,"sd":null},{"arm":"Placebo","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":22,"countries":["United States"]},"refs":{"pmids":["26466871"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":57},"commonTop":["Nasopharyngitis","Crystal urine present","Protein urine present","Headache","Arthralgia"]}}